会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 56. 发明申请
    • A HUMAN G PROTEIN COUPLED RECEPTOR
    • 人类G蛋白偶联受体
    • WO2003031621A2
    • 2003-04-17
    • PCT/US2002/032599
    • 2002-10-11
    • AMERSHAM BIOSCIENCES (SV) CORPZHANG, Jian
    • ZHANG, Jian
    • C12N15/12
    • C12Q1/6883A01K2217/05A61K38/00C07K14/705C07K2319/00C12Q2600/156C12Q2600/158
    • The invention provides isolated nucleic acids that encode GPCR-A-l, and fragments thereof, vectors for propagating and expressing GPCR-A-l nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel GPCR-A-l isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human GPCR-A-l nucleic acids, and transgenic cells and non- human organisms with targeted disruption of the endogenous orthologue of the human GPCR-A-l gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the GPCR-A-l nucleic acids, proteins, and antibodies of the present invention.
    • 本发明提供了编码GPCR-A1的分离的核酸及其片段,用于繁殖和表达GPCR-A1核酸的载体,包含本发明的核酸和载体的宿主细胞,蛋白质, 蛋白质片段和新型GPCR-A1同种型的蛋白质融合物及其抗体。 本发明进一步提供了包含人GPCR-A-1核酸的转基因细胞和非人生物体,以及具有靶向破坏人GPCR-A-1基因的内源直系同源物的转基因细胞和非人生物体。 本发明进一步提供了本发明的核酸,蛋白质和抗体的药物制剂,以及基于本发明的GPCR-A-1核酸,蛋白质和抗体的诊断,研究和治疗方法。
    • 60. 发明申请
    • NOVEL CABERGOLINE DERIVATIVES
    • 新型CABGGOLINE衍生物
    • WO2013191704A1
    • 2013-12-27
    • PCT/US2012/043687
    • 2012-06-22
    • MAP PHARMACEUTICALS, INC.ZHANG, JianARMER, Thomas, A.
    • ZHANG, JianARMER, Thomas, A.
    • A01N43/42A61K31/44
    • C07D457/06C07D457/04
    • Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing dopaminergic D 2 receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT 2 serotonin receptors using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT ID and/or the 5-HT IB receptor, without agonizing (or very weakly agonising) the 5-HT 2B receptor using the compounds and compositions disclosed herein.
    • 本文提供新颖的卡麦角林类似物及其组合物。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物治疗,预防或改善各种医学病症例如偏头痛和帕金森病的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物来激发多巴胺能D2受体和/或拮抗或抑制受体如5-HT2血清素受体的活性的方法。 在其它实施方案中,本文提供的是使用所公开的化合物和组合物来激发受体(例如5-HTID和/或5-HTIB受体)的方法,而不会激动(或非常弱地激动)5-HT 2B受体 于此。